Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Comera Life Sciences Holdings, Inc.CMRA · Entity 94670 | Director | November 09, 2023 | November 14, 2023 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | June 04, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Comera Life Sciences Holdings, Inc.
Report date November 09, 2023 · Filed November 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2033-11-09 | Direct | 111,494 |
Reported balance
After 2023-11-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-09 · Grant · Acquired 111,494 · Balance 111,494 F2: In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,792. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022. F1: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant.
F2: In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,792. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.
PMV Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | Direct | 42,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kura Oncology, Inc.
Report date January 27, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,605 |
Reported balance
After 2023-01-27 transaction · row 1
1 source rowRow 1 · 2023-01-27 · Sale · Disposed 1,906 · Balance 20,605 F1: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. |
Filing footnotes · ownership attribution and instrument terms
F1: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 5, 2026 20:23 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001797209-26-000002 · form4-06052026_080614.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 33,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-016259 · form4-06092025_080616.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:17 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-24-016202 · form4-06102024_080652.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. Read SEC document |
| November 09, 2023 Filed Nov 14, 2023 21:31 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 111,494 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001062993-23-020808 · form4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,494 Underlying: Common Stock · 111,494 shares Expires 2033-11-09 F2 · price: In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,792. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022. F1 · derivative.exercise_date: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 20:41 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 67,172 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001062993-23-017435 · form4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,172 Underlying: Common Stock · 67,172 shares Expires 2033-08-10 F1 · date: The option grant was approved by the registrant's board of directors on August 10, 2023, subject to stockholder approval of an amendment to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the "Plan") under which the option was granted. The registrant's stockholders approved the Plan amendment on August 31, 2023. F3 · price: In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended June 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,375. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022. F2 · derivative.exercise_date: The options became fully vested on the date the Plan amendment was approved by the registrant's stockholders. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:13 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-23-036373 · doc4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:49 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 39,491 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001062993-23-011254 · form4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,491 Underlying: Common Stock · 39,491 shares Expires 2033-05-12 F2 · price: In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended March 31, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,375. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022. F1 · derivative.exercise_date: Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:29 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Purchase) · Derivative | 7,100 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001062993-23-003843 · form4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,100 Underlying: Common Stock · 7,100 shares Expires 2033-02-14 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments beginning on March 14, 2023 such that the option will be fully vested on February 14, 2024, subject to continuous service to the issuer through each vesting date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:17 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,906 | $13.89 | $26,474.34 |
DisclosureSEC source: 0001209191-23-005748 · doc4.xml · nonDerivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · CCO & Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,605 F1 · acquired: Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 1/26/22. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:14 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantWarrants (right to buy) · Derivative | 13,513 | $0.25 Strike: $1.23 | $3,378.25 |
DisclosureSEC source: 0001062993-23-000607 · form4.xml · derivative · entry 2 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,513 Underlying: Common Stock · 27,026 shares Expires 2028-01-04 F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 13,513 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules. F2 · shares: The exercisability of the Warrants is subject to a 4.99% beneficial ownership limitation. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 21:14 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantCommon Stock | 13,513 | $1.23 | $16,620.99 |
DisclosureSEC source: 0001062993-23-000607 · form4.xml · nonDerivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,199 F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 13,513 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules. Read SEC document |
| January 04, 2023 Filed Feb 14, 2023 22:27 UTC Amendment | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrant (Right to Buy) · Derivative | 13,513 | $0.25 Strike: $1.23 | $3,378.25 |
DisclosureSEC source: 0001062993-23-003492 · form4a.xml · derivative · entry 2 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,513 Underlying: Common Stock · 27,026 shares Expires 2028-01-04 F2 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 13,513 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules. F1 · kind: This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person. F3 · shares: The exercisability of the Warrants is subject to a 4.99% beneficial ownership limitation. Read SEC document |
| January 04, 2023 Filed Feb 14, 2023 22:27 UTC Amendment | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseCommon Stock | 13,513 | $1.23 | $16,620.99 |
DisclosureSEC source: 0001062993-23-003492 · form4a.xml · nonDerivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,199 F1 · kind: This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person. F2 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 13,513 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:36 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 19,500 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0001209191-22-034618 · doc4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2032-06-01 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 2, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 19, 2022 Filed Feb 14, 2023 23:02 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | GrantStock Option (Right to Buy) · Derivative | 44,981 | Not disclosed Strike: $0.59 | Not disclosed |
DisclosureSEC source: 0001062993-23-003525 · form5.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,981 Underlying: Common Stock · 44,981 shares Expires 2031-09-16 F2 · price: This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company. F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments beginning on September 16, 2021. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 171,000 | $0.00 Strike: $14.15 | $0.00 |
DisclosureSEC source: 0001209191-22-005374 · doc4.xml · derivative · entry 2 FLOWERS KIRSTEN · CIK 0001797209 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 171,000 shares Expires 2032-01-25 F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 26, 2022 Filed Jan 28, 2022 21:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantCommon Stock | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005374 · doc4.xml · nonDerivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,511 F1 · shares: Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/23, 1/26/24, 1/26/25 and 1/26/26. F2 · balance_after: Includes 611 shares acquired on November 20, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | Exercise / conversionStock Option (right to buy) · Derivative | 32,677 | $0.00 Strike: $19.06 | $0.00 |
DisclosureSEC source: 0001209191-22-002722 · doc4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,677 Underlying: Common Stock · 32,677 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on February 6, 2022. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 22:29 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 125,000 | $0.00 Strike: $32.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005912 · doc4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 06, 2020 Filed Jan 7, 2020 21:10 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 250,000 | $0.00 Strike: $13.85 | $0.00 |
DisclosureSEC source: 0001209191-20-002242 · doc4.xml · derivative · entry 1 FLOWERS KIRSTEN · CIK 0001797209 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-01-05 F1 · derivative.exercise_date: 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.